Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New hope for patients with rare genetic diseases

23.08.2005


Because of the very high costs in developing drugs for rare genetic diseases, and the low return on investment, the pharmaceutical industry has rarely developed specific treatments for many of these diseases. But a new public-private partnership, called the European Rare Diseases Therapeutic Initiative (ERDITI), could provide an important new mechanism for developing new drugs.



In an article in this month’s open access international medical journal PLoS Medicine, Alain Fischer, Head of the Department of Pediatric Immunology at the Necker University Hospital, Paris, France, and colleagues describe how ERDITI (www.erditi.org) is bringing drug companies and academic researchers together to find new treatments for rare diseases.

"The thousands of compounds that have been developed by pharmaceutical companies for more common diseases but that were abandoned or failed to achieve registration for several reasons (such as biopharmaceutical properties, toxicity, lack of efficacy, or strategic reasons) represent a treasure worth exploiting," say the authors.


The idea behind ERDITI is that participating drug companies give these "abandoned" compounds to academic researchers who then investigate whether the compounds might be effective for treating rare diseases. Companies benefit from this relationship with academia in many ways, say the authors--for example, by demonstrating corporate social responsibility. The research on treatments for rare diseases may also lead to the discovery of drugs for the treatment of more common diseases, which could be highly profitable to industry.

The ERDITI partnership between industry and academia, say the authors, is governed by a charter of collaboration which includes "a standard agreement that describes the objectives of the research and defines the framework for the transfer and use of compounds. It also defines the rights and obligations of each party in terms of protection of information, intellectual property, and industrial property."

Paul Ocampo | EurekAlert!
Further information:
http://www.plos.org
http://www.plosmedicine.org

More articles from Health and Medicine:

nachricht The end of pneumonia? New vaccine offers hope
23.10.2017 | University at Buffalo

nachricht Scientists track ovarian cancers to site of origin: Fallopian tubes
23.10.2017 | Johns Hopkins Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Salmonella as a tumour medication

HZI researchers developed a bacterial strain that can be used in cancer therapy

Salmonellae are dangerous pathogens that enter the body via contaminated food and can cause severe infections. But these bacteria are also known to target...

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

3rd Symposium on Driving Simulation

23.10.2017 | Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

 
Latest News

Shrews shrink in winter and regrow in spring

24.10.2017 | Life Sciences

Microfluidics probe 'cholesterol' of the oil industry

23.10.2017 | Life Sciences

Gamma rays will reach beyond the limits of light

23.10.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>